Background: Most human genetic association studies have been undertaken in populations of European ancestry, despite >75% of the world's population being of Asian or African ancestry. In addition, many of the non-white genetic studies have had small sample sizes and lack replication. To date, >80 different genetic variants have been identified for late-onset Alzheimer's disease (AD) using populations mainly of European ancestry and from high income countries, despite more than ∼60% of dementia cases living in low and middle-income countries. There is a need to evaluate genetic risk of dementia and related phenotypes in under-represented populations, such as the multi-ethnic cohorts of the Cohort Studies of Memory in an International Consortium (COSMIC). Polygenic risk scores (PRS) summarise the known genetic risk for a particular disorder or trait, such as dementia. But the applicability and generalisability of dementia PRSs based on genetic studies of European ancestry is unclear. This study aims to examine the utility and performance of dementia polygenic risk scores (PRSs) derived from European, non-European, and trans-ethnic samples for dementia diagnosis and its associations with cognitive impairment in COSMIC studies.
Method: COSMIC participants (middle-aged to older adults) with genome-wide genotyping, cognitive and dementia data will be included. Genotypes will be imputed to the appropriate reference panel/s. PRSs will be derived using the appropriate GWAS summary statistics based on European and non-European based cohorts and trans-ethnic analyses for the two most common types of dementia (Alzheimer's disease [AD], vascular dementia [VaD]). Association analyses for the phenotypes of AD, VaD, and cognitive performance will be undertaken using regression adjusting for age, sex, and any other specific covariates.
Result: There are at least 14 COSMIC cohorts with genotyping and dementia/cognitive data available who have recruited participants of European and non-European ancestry (n>15K), including studies from Japan, South America, Africa, India, and China. Performance of PRSes computed under various models for predicting dementia and cognitive impairment will be presented.
Conclusion: This work will elucidate the utility of specific and multi-ethnic dementia PRSs predicting the risk of dementia and its endophenotype, cognitive impairment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.087350 | DOI Listing |
Dermatitis
January 2025
From the Department of Orthopedics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Eczema and dermatitis are common inflammatory skin conditions with significant morbidity. Identifying drug-targetable genes can facilitate the development of effective treatments. This study analyzed data obtained by meta-analysis of 2 genome-wide association studies on eczema/dermatitis (57,311 cases and 896,779 controls, European ancestry).
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania.
Importance: Recently, the US Food and Drug Administration gave premarketing approval to an algorithm based on its purported ability to identify individuals at genetic risk for opioid use disorder (OUD). However, the clinical utility of the candidate genetic variants included in the algorithm has not been independently demonstrated.
Objective: To assess the utility of 15 genetic variants from an algorithm intended to predict OUD risk.
JAMA Oncol
January 2025
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Importance: Although differences in the prevalence of key cancer-specific somatic mutations as a function of genetic ancestry among patients with cancer has been well-established, few studies have addressed the practical clinical implications of these differences for the growing number of biomarker-driven treatments.
Objective: To determine if the approval of precision oncology therapies has benefited patients with cancer from various ancestral backgrounds equally over time.
Design, Setting, And Participants: A retrospective analysis of samples from patients with solid cancers who underwent clinical sequencing using the integrated mutation profiling of actionable cancer targets (MSK-IMPACT) assay between January 2014 and December 2022 was carried out.
Transl Vis Sci Technol
January 2025
Department of Otolaryngology & Head and Neck Surgery, Wuhan No.1 Hospital, Wuhan, Hubei, China.
Purpose: Previous researches have suggested an important association between gut microbiota (GM) and vascular pathologies such as atherosclerosis. This study aimed to explore the association between 196 GM taxa and retinal vein occlusion (RVO).
Methods: This study used Mendelian randomization (MR), linkage disequilibrium score regression (LDSC), and polygenic overlap analysis.
JAMA Netw Open
December 2024
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis.
Importance: Identification of individuals at high risk of alcohol use disorder (AUD) and subsequent application of prevention and intervention programs has been reported to decrease the incidence of AUD. The polygenic score (PGS), which measures an individual's genetic liability to a disease, can potentially be used to evaluate AUD risk.
Objective: To assess the estimability and generalizability of the PGS, compared with family history and ADH1B, in evaluating the risk of AUD among populations of European ancestry.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!